DOI: 10.1177/03331024261435922 ISSN: 0333-1024

SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study)

Claudia Altamura, Luigi Francesco Iannone, Flavia Lo Castro, Gabriele Sebastianelli, Marilena Marcosano, Federico De Santis, Michele Corrado, Raffaele Ornello, Licia Grazzi, Danilo Antonio Montisano, Francesco De Cesaris, Antonio Munafò, Gianluca Avino, Michele Trimboli, Maria Albanese, Antonio Russo, Marcello Silvestro, Giorgio Dalla Volta, Marina Romozzi, Paolo Calabresi, Alberto Boccalini, Paola Merlo, Maria Pia Prudenzano, Maria Rosaria Valente, Innocenzo Rainero, Giada Giuliani, Marta Altieri, Luisa Fofi, Alberto Doretti, Gloria Vaghi, Francesca Pistoia, Delfina Ferrandi, Stefania Battistini, Gianluca Coppola, Simona Guerzoni, Simona Sacco, Cristina Tassorelli, Fabrizio Vernieri,
Show PDF Cite

Background

The improved prevention of migraine, driven by the introduction of calcitonin gene-related peptide (CGRP)-targeted therapies, has prompted the International Headache Society (IHS) to propose new goals in migraine management. This study aimed to evaluate the safety and effectiveness of atogepant for migraine prevention over 24 weeks, in accordance with the IHS-defined goals.

Methods

This is a multicenter, prospective, observational, real-world study on patients starting atogepant 60 mg for migraine prevention. We describe efficacy and safety outcomes at weeks 9–12 (T3) and 21–24 (T6) relative to baseline (T0) from the initiation of atogepant treatment. We also report the proportion of patients achieving migraine freedom, optimal, modest or insufficient control according to the IHS position paper categories.

Results

One hundred twenty-eight ( n  = 128) patients (63 (49.2%) with chronic migraine, 115 (89.9%) female, aged 48.3 ± 13.3 years) from 17 centers were analyzed. Monthly migraine days decreased from 16.5 ± 8.5 at T0 to 8.0 ± 8.4 at T3 ( p  < 0.001 vs. T0) and 8.6 ± 9.2 at T6 ( p  < 0001 vs. T0, p  = 0.265 compared to T3). Overall, 64.8% of patients were responders (at least 50% reduction in monthly migraine days from T0) at T3 and 61.7% at T6; 81.9% of responders at T3 maintained the responder status at T6, while 24.4% of patients among non-responders at T3 became responders at T6. At T3 and T6, 39.1% of the entire cohort achieved at least optimal migraine control (20.6% in chronic migraine and 56.9% in episodic migraine).

Conclusions

The STAR study demonstrates, in a real-world setting, the safety and the sustained effectiveness of atogepant 60 mg over 24 weeks and indicates that more than one-third of treated patients can achieve at least optimal disease control, with markedly better outcomes in episodic than in chronic migraine.

Trial Registration

The study was preregistered on clinicaltrial.gov, NCT06414044.

More from our Archive